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Background: P276-00 is a novel cyclin-dependent kinase inhibitor currently in Phase II clinical trials. Gemcitabine is
a standard of care for the treatment of pancreatic cancer. The present study investigated the effect of the
combination of P276-00 and gemcitabine in five pancreatic cancer cell lines.
Methods: Cytotoxic activity was evaluated by Propidium Iodide assay. Cell cycle and apoptosis was analyzed by
flow cytometry. Genes and proteins known to inhibit apoptosis and contribute to chemoresistance were analysed
using western blot analysis and RT-PCR. In vivo efficacy was studied in PANC-1 xenograft model.
Results: The combination of gemcitabine followed by P276-00 was found to be highly to weakly synergistic in
various pancreatic cancer cell lines as assessed by the combination index. Enhancement of apoptosis in PANC-1
cells and decrease in the antiapoptotic protein Bcl-2 and survivin was seen. P276-00 potentiated the
gemcitabine-induced cytotoxicity by modulation of proteins involved in chemoresistance to gemcitabine and
cell cycle viz. antiapoptotic proteins p8 and cox-2, proapoptotic protein BNIP3 and cell cycle related proteins Cdk4
and cyclin D1. The above results could explain the novel mechanisms of action of the combination therapy. We
also show here that gemcitabine in combination with P276-00 is much more effective as an antitumor agent
compared with either agent alone in the PANC-1 xenograft tumor model in SCID mice.
Conclusions: The chemosensitzation of pancreatic tumors to gemcitabine would likely be an important and novel
strategy for treatment of pancreatic cancer and enable the use of lower and safer concentrations, to pave the way
for a more effective treatment in this devastating disease. Phase IIb clinical trials of P276-00 in combination with
gemcitabine in pancreatic cancer patients are ongoing.
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Pancreatic adenocarcinoma is one of the leading causes
of cancer death with mortality rates almost identical to
incidence rates [1]. Diagnosis usually occurs at late
stages, making surgical intervention almost unfeasible
due to low survival rates [2]. Standard treatments for
advanced disease include radiotherapy and/or chemo-* Correspondence: kalpana.joshi@piramal.com
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reproduction in any medium, provided the ortherapy regimens. Radiotherapy has been shown to have
some utility for regional confined cancers, but it is often
too toxic for tissues surrounding the neoplasis. Widely
used chemotherapeutic regimens include 5-fluorouracil
(5-FU) and gemcitabine, a nucleoside analogue of
cytidine (2’, 2’-difluorodeoxycytidine; dFdC) [3]. How-
ever, even gemcitabine, which is now considered the
gold standard, has a response rate of less than 20%,
although it does provide an improvement in the qual-
ity of life [4]. It is clear that novel therapeutic agents
and/or combinations are needed for the treatment of
pancreatic cancer.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mutations and/or silencing of tumor suppressor genes,
such as p53 and Smad4, the overexpression of mito-
genic growth factors and their cognate high affinity
tyrosine kinase receptors, and mutation of K-ras [5].
There are also defects in cell cycle-regulating genes, such
as the increased expression of cyclin D1 and mutation/
silencing of p16, which contribute to the inactivation of
the retinoblastoma protein [6]. These alterations contrib-
ute to the excessive growth of pancreatic tumors and to
the resistance of pancreatic cancers to chemotherapeutic
agents [7].
Deregulated cell cycle progression has been considered
as the hallmark of cancer progression, and therefore, is a
practical target for anti-cancer drug development [8-11].
Cdks regulate the cell cycle progression, and their activ-
ity is increased in cancer cells. Accordingly, pursuits for
the drugs that inhibit Cdks have been the intense area of
research for last two decades, and numerous Cdk inhibi-
tors have been identified. These drugs have been classi-
fied as pan-Cdk inhibitors or selective Cdk inhibitors
[12]. The novel synthetic flavonoid P276-00 currently
undergoing several Phase II clinical trials potently inhi-
bits three specific cyclin-dependent kinase (Cdk) com-
plexes, Cdk1/cyclin B, Cdk4/cyclin D1 and Cdk9/cyclin
T. It exhibits an excellent anti-proliferative activity
against panel of cancer cell lines including pancreatic
adenocarcinoma cell lines and shows high efficacy in
SCID mice tumour models [13,14].
Combination therapy is a major strategy for over-
coming drug resistance and improving responses and
cure rates. Cell cycle based agents have shown tremen-
dous promise and potential against cancer; however,
they are not fully effective by themselves. Similarly,
cancer chemotherapies, which are the mainstream
treatments for various human malignancies, are pla-
gued by toxicity and the development of drug resist-
ance, decreasing their overall clinical usefulness.
Combining these two different categories of drugs has
shown decreased toxicity and chemoresistance along
with increased efficacy, suggesting that this could be
an ideal approach to lower the cancer burden. Because
P276-00 has potent antitumor activity in human pan-
creatic cancer cell lines and gemcitabine is currently
used as first-line treatment for patients with locally
advanced or metastatic cancer of the pancreas, the
current work was undertaken to determine if they can
be used in combination, thereby providing additive or
synergistic benefits against pancreatic cancer. We thus
evaluated the growth inhibitory potential of P276-00,
gemcitabine and their combination in a panel of
human pancreatic cancer cell lines and their in vivo
antitumor efficacy against a human pancreatic cancer
(PANC-1) xenograft.Methods
Cell culture
Human pancreatic cancer cell lines, PANC-1, AsPC-1,
MIA PaCa-2, BxPC-3 and Capan-1 were purchased from
the American type Culture Collection, USA. The PANC-
1 cell line was routinely cultured in MEM with NEAA
(non-essential amino acids from SAFC biosciences),
AsPC-1, MIA PaCa-2 and BxPC-3 in RPMI-1640 with
10% fetal bovine serum, Capan-1 in IMDM with L-
glutamine and 20% serum and maintained as adherent
cultures at 37°C in a humidified atmosphere containing
5% CO2.
In vitro cytotoxicity assay
Cells were plated in 96-well cell culture plates (4 × 103
cells/well) and were treated with P276-00 and /or gemci-
tabine at the indicated concentrations. Treated cells
were maintained at 37°C in 5% CO2 for times indicated
in the legends to the figures. A modified propidium iod-
ide (PI) assay was used to assess the effects of the com-
pounds on the growth of the human tumor cell lines
[15]. Following continuous drug exposure, cell culture
medium with or without drug was replaced by 200 μl of
an aqueous PI solution (7 μg/mL). Because PI only
passes leaky or lysed cell membranes, DNA of dead cells
will be stained and measured, whereas living cells will
not be stained. To measure the proportion of living cells,
cells were permeabilized by freezing the plates, resulting
in death of all cells. After thawing of the plates, fluores-
cence was measured using the POLARstar OPTIMA
from BMG Technologies (excitation, 544 nm; emission,
620 nm), giving a direct relationship to the total cell
number. IC50 values were determined by plotting com-
pound concentration versus cell viability. The combin-
ation index (CI) was calculated by the Chou-Talalay
equation, which takes into account both the potency and
the shape of the dose-effect curve taking advantage of
the Compusyn software (ComboSyn, Inc. NY, USA). The
combination index is used for the quantification of syn-
ergism or antagonism for two drugs where CI < 1, =1,
and >1 indicate synergism, additive effect, and antagon-
ism, respectively.
Cell cycle analysis
Cell cycle distribution was analyzed using propidium
iodide (PI)-stained cells. Cells were cultured in 100-mm
petri dishes and allowed to grow to 75-80% confluency.
The cells are then treated with the drugs of interest at
the indicated concentrations and time period and com-
pared with control samples not exposed to drug. After
drug exposure, cells were trypsinized, washed with PBS,
resuspended and fixed with cold 70% ethanol. Samples
were stored at −20°C before analysis. When samples
are to be analyzed, they are centrifuged, the ethanol
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resuspended in PBS containing 50 μg/mL PI and 50 μg/
mL RNaseA. After incubation at room temperature for
20 min, cells were analyzed by flow cytometry using
the Becton Dickinson (San Jose, CA) FACS Calibur
flow cytometer.RNA extraction and reverse transcription-PCR
Total RNA extraction was performed from cultured cells
using RNA easy kit (Qiagen, Valencia, CA) according to
the manufacturer’s protocol, and purified RNA was
quantitated and assessed for purity by UV spectropho-
tometry. cDNA was generated from 5 μg of RNA with
Superscript III reverse transcriptase (Qiagen). The amp-
lification of each specific RNA was performed in a 20 μl
reaction mixture containing 2 μl of cDNA template, 1X
PCR master mix, and the primers. The PCR primers
used for detection of BNIP3 was from Superarray with
annealing temperature of 60°C and cycle no. 22. Simi-
larly for p8: Forward primer TAGAGACGGGACTGCG;
Reverse primer GCGTGTCTATTTATTGTTGC with
annealing temperature of 57°C and cycle no. 35. Cox-2:
Forward primer TTCAAATGAGATTGTGGGAAAATT
GCT; Reverse primer AGATCATCTCTGCTTGAGTA
TCTT with annealing temperature of 60°C and cycle no.
32. Tubulin Forward primer TCTGTTCGCTCAGG
TCCTTTTGGCC; Reverse primer CGTACCACATC
CAGGACAGA with annealing temperature of 55°C and
cycle no. 22 were used. The PCR products were loaded
onto 1.5% agarose gels and visualized with ethidium
bromide under UV light. As a control for cDNA synthe-
sis, reverse transcription-PCR was also performed using
primers specific for β-actin gene.Immunoblot analysis
Protein extracts from PANC-1 cells, untreated or treated
with P276-00, gemcitabine or both were prepared by
suspending the cells in cell lytic buffer (Sigma) and Pro-
tease inhibitor cocktail (Sigma). The lysate was clarified
by centrifugation to remove debris. For immunoblotting,
each extract was prepared as above and an equivalent to
50 μg total protein was separated on SDS-PAGE, elec-
trotransferred onto PVDF membranes. Membranes were
probed with specific antibody to cyclin D1, Cdk4, Bcl-2,
survivin (Santacruz Biotecnology), BNIP3 (Sigma),
COX-2 (CalBiochem). Horseradish peroxidase conju-
gated anti-mouse or ant-rabbit IgG (Santacruz Biotech-
nology) was used to detect specific proteins. β-actin
antibody (Sigma) was used as an internal control for
protein loading. Detection of specific proteins was
carried out with an enhanced chemiluminescence west-
ern blotting kit (Pierce) according to manufacturer’s
instructions.In vivo studies
To examine the in vivo antitumor efficacy, PANC-1 cells
(5 × 106) cancer cells per mice were injected s.c. into
6 weeks old male SCID mice. Once the tumors attained
a size of ~10 mm, animals were randomized to four ex-
perimental groups to receive vehicle control (saline) or
P276-00 or gemcitabine or both. Gemcitabine was admi-
nistered on day 1 and day 6 while P276-00 was adminis-
tered once every day from day 2–5 and day 7–10. The
first dose of gemcitabine was followed by P276-00 after
an interval of 24 h, followed everyday with P276-00 for a
total of five days, which comprised of one cycle. The
next cycle would begin the next day. The treatment
comprised of total 2 cycles. Body weight was recorded
everyday. Tumor size and other signs of toxicity were
recorded on every alternate day without sacrificing the
mice. Tumor measurements i.e. the length and width of
the tumors were measured using the vernier caliper.
Tumor weight (mg) was estimated according to the for-
mula for a prolate ellipsoid: {Length (mm) × [width
(mm)2] × 0.5} assuming specific gravity to be one and π
to be three. Tumor growth in compound treated animals
is calculated as T/C (Treated/Control) × 100% and
Growth inhibition Percent (GI%) was [100-T/C%].Results and discussion
Effect of P276-00 and gemcitabine on cell proliferation
Cdk inhibitor P276-00 has been shown to induce cell
cycle arrest and apoptosis of human tumor derived cell
lines [13,14]. To elucidate the effects of the Cdk inhibi-
tor P276-00 in pancreatic cancer cell lines, five pancre-
atic cancer cell lines AsPC-1, BxPC-3, Capan-1, MIA
PaCa-2 and PANC-1 with varying genetic status and
sensitivity to gemcitabine were treated with increasing
concentrations (0–10 μM) of P276-00 for 48 h and cell
proliferation was assessed by Propidium Iodide
(PI assay). Treatment with P276-00 caused a dose-
dependent decrease in the proliferation of all the five cell
lines (Figure 1A). The results indicated that P276-00 was
overall an effective inhibitor as a single agent for pancre-
atic cancer cell growth with both wild type and mutated
K-ras. Except for BxPC-3 all the other 4 cell lines were
K-ras mutated. MIA PaCa-2 and PANC-1 were more
sensitive (2–3 times) than AsPC-1, BxPC-3 and Capan-1
as seen from the IC50 values (Figure 1B and Table 1).
We also evaluated the effect of gemcitabine on cell
growth in vitro and found that gemcitabine was effective
in inhibiting cell growth of all the five cell lines
(Figure 1C). BxPc-3 was highly sensitive to gemcitabine
while AsPC-1 and PANC-1 was moderately sensitive.
Capan-1 and MIA PaCa-2 were comparatively more re-



















































Figure 1 The effect of P276-00 and gemcitabine treatment on growth of five pancreatic cancer cell lines. Cells were seeded in 96-well
plates and incubated overnight. P276-00 or gemcitabine was added at the indicated concentrations and cells were further incubated for 48 h.
Cell proliferation was determined using PI assay. (A & B) The 50% inhibitory concentration of P276-00 in five different pancreatic cancer cell lines.
(C & D) The 50% inhibitory concentration of gemcitabine in five different pancreatic cancer cell lines.
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gemcitabine in various human pancreatic cancer cell lines
The nucleoside analogue gemcitabine is commonly used
in pancreatic cancer treatment regimens. However, gem-
citabine is not curative in pancreatic cancer and treat-
ment only increases survival by a few months [16]. To
determine if P276-00 enhances the sensitivity of pancre-
atic cells to the growth inhibitory/apoptotic effect of
gemcitabine, proliferation assays were done. For these
studies, cells were either treated with P276-00 (corre-
sponds to IC50 concentration at 48 h for each of the cell
lines) or gemcitabine alone or in combination with serial
concentrations of gemcitabine (10–1000 nM) followed
by P276-00 for a period of 72 h or 96 h and viable
cells were evaluated at 72 h or 96 h post treatment byTable 1 IC50 values of P276-00 and gemcitabine in the
different pancreatic cancer cell lines
Cell line P276-00 IC50 (μM) Gemcitabine IC50 (nM)
AsPC-1 1.58 ± 0.22 190± 14.14
BxPC-3 1.6 ± 0.14 80 ± 14.14
Capan-1 1.67 ± 0.12 666.7 ±115.5
MIA PaCa-2 0.83 ± 0.16 733.3 ± 57.7
PANC-1 0.58 ± 0.09 225± 31.09PI assay. Combination treatment yielded significantly
greater growth inhibition in a dose-dependent manner
than either agent alone in all the cell lines tested
(Figure 2). Treatment with P276-00 plus gemcitabine sim-
ultaneously was synergistic however, pretreatment of cells
with P276-00 was antagonistic (data not shown). The
combination index method developed by Chou and Tala-
lay [17] were used to confirm and quantify the synergism
observed with gemcitabine and P276-00. Combination
index (CI) <1 is evidence for synergy, whereas CI >1 is
evidence of antagonism, and CI= 1 indicates simple
additivity of drug effect. The CI values of the combin-
ation of IC50 of P276-00 with various concentration of
gemcitabine were calculated using CompuSyn software.
BxPC-3 which is K-ras WT being the most sensitive cell
line to gemcitabine was highly synergistic with P276-00
with CI values ranging from 0.38 –0.69 at all concentra-
tions of gemcitabine ranging from 30 –1000 nM after
72 h of P276-00 treatment. The moderately sensitive cell
lines to gemcitabine and K-ras mutated, AsPC-1 and
PANC-1 were moderately synergistic with CI in the
range of 0.86-0.89 and 0.6-0.72 respectively at concen-
trations of gemcitabine ranging from 30–300 nM after
72 h of P276-00 treatment. The two resistant cell lines
to gemcitabine Capan-1 and MIA PaCa-2 were weakly
BxPC-3 (72 h of P276-00)
AsPC-1 (72 h of P276-00 treatment) 
P276-00 (1.5 µM): 48% 
CI: 0.86–0.89 
P276-00 (1.5 µM): 78% 
CI: 0.71-0.95 
Panc-1 (72 h of P276-00treatment)
Capan-1 (96 h of P276-00 treatment) 
P276-00 (0.6 µM): 38% 
CI: 0.6-0.72 
P276-00 (1.6 µM): 69% 
CI: 0.91-0.93 
Mia PaCa-2 (96 h of P276-00 treatment)  
P276-00 (0.7 µM): 47% 
CI: 0.71-0.95
Figure 2 Effect of P276-00 and gemcitabine used singly or in combination on survival of BxPC-3, AsPC-1, PANC-1, Capan-1 and MIA PACA-2
pancreatic cancer cell lines. The cells were treated as described under Materials and Method section. There was significantly higher growth inhibition of the
cells treated with gemcitabine (24 h) followed by P276-00 at IC50 concentration (1.5, 1.5, 1.6, 0.7 and 0.6 μM for AsPC-1, BxPC-3, Capan-1, MIA PaCa-2 and
PANC-1 respectively) for 72 h or 96 h compared to the cells treated with either agent alone. P276-00 treatment alone in BxPC-3, AsPC-1, PANC-1, Capan-1 and
MIA PaCa-2 showed 78%, 48%, 38%, 69% and 47% survival respectively.
Table 2 Synergistic range in different pancreatic cancer
cell lines with varying genetic status
AsPC-1 BxPc-3 Capan-1 MIA PaCa-2 PANC-1
K-ras mut wt mut mut mut
p53 nk mut mut mut mut
p16 nk - - - -
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and 0.71-0.95 respectively at concentrations of gemcita-
bine ranging from 500–700 nM after 96 h of P276-00
treatment. For all further studies, PANC-1 cell line
which is moderately sensitive to gemcitabine and K-ras
mutated was used as K-ras mutation is found in 90% of
pancreatic cancers (Table 2).P276-00 R R R MS MS
Gemcitabine MS S R R MS
G+ P276-00 (CI) MSy HSy WSy MSy MSy
(0.86-0.89) (0.38-0.69) (0.9-0.93) (0.71-0.95) (0.6-0.72)
nk: not known -: deletion mut: mutated wt: wild type.
S: sensitive MS: moderately sensitive R: resistant.
WSy: weakly synergistic MSy: moderately synergistic HSy: highly synergistic.P276-00 sensitizes PANC-1 cells to apoptosis induced
by gemcitabine
The above results were also confirmed by cell cycle
analysis using flow cytometry wherein induction of
apoptosis in PANC-1 cells treated with either P276-00
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observed. Relative to single agents, gemcitabine (70 nM)
pretreatment followed by P276-00 (300 nM) treatment
for 72 or 96 h induced time dependent apoptosis in
PANC-1 cell line as shown by cell cycle analysis using
flow cytometry (Figure 3A and 3B). The percent distri-
bution of the cells in various phases of the cell cycle
is also depicted in the bar graph as shown in
Figure 3B. The combination of P276-00 and gemcita-
bine showed highly significant apoptosis of 25.4% and
73% at 96 h and 120 h respectively as compared to
either drug alone (p < 0.001). The expression of the
antiapoptotic proteins Bcl-2 and survivin after treat-
ment with P276-00 or gemcitabine or both wasA. 
C. 
D. 
Figure 3 The effect of P276-00, gemcitabine and the combination of
300 nM P276-00 for 72 h or 70 nM of gemcitabine for 24 h followed by on
gemcitabine for 24 h followed by P276-00 for 72 h. (B) Cells were treated w
followed by only medium for additional 96 h or combination treatment of
using Flow cytometry shows the percentage apoptosis in drug alone and c
percent distribution of cells in various phases of the cell cycle is represente
antiapoptotic proteins Bcl-2 and survivin. Samples were obtained from PAN
24 h or the combination of gemcitabine for 24 h followed by P276-00 for 7
the software Image J.examined by Western blotting. As shown in the
Figure 3C and the corresponding densitometry plot of
the western bands in Figure 3D, the combination of
P276-00 and gemcitabine decreased the expression of
both antiapoptotic proteins Bcl-2 and survivin which
may account for the drug synergy between P276-00
and gemcitabine.
P276-00 regulates the cell cycle related proteins Cdk4
and cyclin D1 induced by gemcitabine
Next, we analyzed the effect of gemcitabine on Cdk4
and cyclin D1, which are necessary for cell cycle pro-
gression, and whether down regulation of these proteins

































































































gemcitabine followed by P276-00 on (A). Cells were treated with
ly medium for additional 72 h or combination treatment of
ith 300 nM P276-00 for 96 h or 70 nM of gemcitabine for 24 h
gemcitabine for 24 h followed by P276-00 for 96 h. Cell cycle analysis
ombination treatment in comparison to untreated control. The
d as bar plot (C) Western blot analysis in PANC-1 cells of the
C-1 cells treated with 300 nM of P276-00 for 72 h or gemcitabine for
2 h. (D) Densitometric analysis of the Bcl-2 and survivin bands using
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tosis. Our results showed that relative to untreated con-
trol, gemcitabine treatment increased both Cdk4 and
cyclin D1 levels as compared to control. Furthermore,
the addition of P276-00 for 72 h to the cells post 24 h
gemcitabine treatment reduced both cyclin D1 and Cdk4
protein levels which were upregulated by gemcitabine
(Figure 4).
P276-00 regulates genes responsible for chemoresistance
to gemcitabine in PANC-1
Next we analyzed whether the genes responsible for che-
moresistance to gemcitabine in PANC-1 could be regu-
lated by P276-00. The three genes studied were the
antiapoptotic genes COX-2, p8 and the proapoptotic gene
BNIP3. The gene expression of all these genes was studied
using RT-PCR in a time dependent manner (Figure 5A).
The densitometry plots of the RT-PCR bands are shown
in Additional file 1: Figure S1. Western blot analysis of
BNIP3 and COX-2 proteins was studied at the end of the
treatment for the combination and drug alone treatment
(Figure 5B). The densitometry plots of the western bands
are shown (Figure 5C). Our results indicated that relative
to untreated control, the combination treatment of 70 nM
gemcitabine followed by 12 h of 300 nM of P276-00
downregulated the gene expression of the antiapoptotic
protein p8 and COX-2. The gene expression of the proa-
poptotic protein BNIP3 is upregulated in the combination
by P276-00 from 3 h onwards. More interestingly it is sig-
nificantly upregulated by P276-00 alone at 24 h. WesternFigure 4 Western blot analysis in PANC-1 cells of the cell cycle protei
treated with 300 nM of P276-00 for 72 h or 70 nM gemcitabine for 24 h or
72 h. (B) Densitometric analysis of the Cdk4 and cyclin D1 bands using theblot analysis also revealed that combination treatment
inhibits antiapoptotic protein COX-2 and enhances the
proapoptotic protein BNIP3.
P276-00 potentiates anti-tumor effect of gemcitabine in
xenograft model of pancreatic cancer
The effects of the combination of P276-00 and gemcita-
bine on human pancreatic PANC-1 tumor xenograft
were studied to determine if the synergy observed
in vitro between P276-00 and gemcitabine also occurred
in vivo. Treatment with either P276-00 (20 mg/kg) or
gemcitabine (40 mg/kg) was initiated when tumors
reached a size of ~10 mm in diameter. P276-00 and
gemcitabine did not cause significant suppression of
tumor growth, while the combination of the two drugs
showed significant reduction in the mean tumor weight
(Figure 6A). The growth inhibition in the combination
treatment was 85% compared to control vs. 60% and
27% in gemcitabine and P276-00 treatment alone re-
spectively (p < 0.05) (Figure 6B). No body weight loss
was observed in both the combination and single drug
treated groups indicating that the doses and schedule
were well tolerated.
Discussion
Despite rapid advances in diagnostic and operative tech-
niques, pancreatic cancer remains one of the most diffi-
cult human malignancies to treat, which is partly due to
the advanced stage of the disease and de novo chemore-
sistant behavior to cytotoxic chemotherapeutic agentsns Cdk4 and cyclin D1. (A) Samples were obtained from PANC-1 cells
the combination of gemcitabine for 24 h followed by P276-00 for
software Image J.
Figure 5 RT-PCR and Western blot analysis in PANC-1 cells. Samples were obtained from PANC-1 cells treated with 300 nM of P276-00
and/or 70 nM gemcitabine at various time points as indicated in the figure. (A) Electrophoretic analysis of BNIP3, p8 and COX-2 mRNA. (B) protein
expression analysis of antiapoptotic protein COX-2 and proapoptotic protein BNIP-3. (C) Densitometric analysis of the COX-2 and BNIP3 bands
using the software Image J.
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been addressed by combinatorial approach. Several ran-
domized studies have shown significant increase in pa-
tient response rate by the use of combinations of
different class of chemotherapeutic agents, but the major
problem is due to treatment associated high toxicity,with no added benefit in significant overall survival
[18-20]. However these limitations could be overcome
by the use of rational chemotherapeutic combinations,
in which toxic agents are used in lower doses, and the
efficacy of treatment is complemented by using another




p < 0.05 
Figure 6 The combination treatment of gemcitabine with
P276-00 showed significant tumor growth inhibition in PANC-1
xenograft model. (A) Differences in the Tumour weight (mg) in the
different treatment groups. (B) Percent growth inhibition after
treatment. Statistically significant difference (p < 0.005) of the
combination treatment of gemcitabine and P276-00 compared with
the control was seen.
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P276-00 in combination with a commonly used che-
motherapeutic agent, gemcitabine, to test its efficacy
against a panel of pancreatic cancer cell lines differing in
their genetic markers and sensitivity to the drugs used.
The preclinical data indicates that P276-00 enhances the
gemcitabine-induced cytotoxicity when added after 24 h
of gemcitabine treatment as compared to either drug
alone irrespective of the genetic status of the various
pancreatic cell lines.
Increased apoptosis with the sequence of gemcitabine
followed by P276-00 was shown by flow cytometry. Con-
centrations of gemcitabine and P276-00 used in this
study resulted in minimal growth inhibitory effects when
used alone. This concentration also resulted in negligible
apoptosis as seen by the sub G1 phase in cell cycle ana-
lysis. However significant apoptosis of 25% and 73% was
noticed when the gemcitabine treated cells were further
exposed to P276-00 at 72 h and 96 h respectively at con-
centration that were suboptimal. The apoptosis in the
combination was ~12 times more than P276-00 alone at
96 h of treatment. It is important to note that the above
concentrations are easily achievable in humans; hence
the in vitro results are expected to be relevant to futurehuman studies. The increased apoptosis in the combin-
ation was also supported by the downregulation of the
anti apoptotic proteins Bcl-2. Survivin, a member of the
inhibitor of apoptosis (IAP) family is selectively expressed
in the most common human neoplasms and appears to be
involved in tumor cell resistance to some anticancer
agents and ionizing radiation [21,22]. Specifically its antia-
poptotic function seems to be related to the ability to dir-
ectly or indirectly inhibit caspases and knockdown of the
survivin gene expression seems to be a promising treat-
ment strategy for cancer treatment. In this study we have
shown that P276-00 and gemcitabine significantly de-
crease survivin levels as compared to either drug alone.
Thus downregulation of Bcl-2 and survivin may be re-
sponsible for the increased apoptotic rate in the combin-
ation treatment of gemcitabine followed by P276-00 in
PANC-1 cells.
P276-00 is a synthetic flavone and a cyclin-dependent
kinase (Cdk) inhibitor in Phase I/II clinical trials at mul-
tiple centers. It has been shown to induce cell cycle ar-
rest at G1 or G2/M, in association with direct inhibition
of Cdk-1, -4, -6 and −9 [13]. Although the mechanisms
of P276-00 induced antiproliferative activity have not
been fully elucidated, inhibition of cyclin-dependent
kinases may contribute to the anticancer effect, along
with additional actions such as promotion of apoptosis,
and a decrease of pRb and cyclin D1. Here we show for
the first time that gemcitabine treatment of PANC-1
cells induces the cell cycle proteins cyclin D1 and Cdk4
and P276-00 when combined with gemcitabine, is cap-
able of significantly reducing these increased protein
levels of cyclin D1 and Cdk4 which are induced by gem-
citabine treatment. Hence the reduction by P276-00 of
these cell cycle proteins required for cell cycle progres-
sion may be one of the mechanisms by which the pan-
creatic cells are sensitized to apoptotic cell death by
gemcitabine.
Resistance to the cytotoxic effect of gemcitabine can
be related to multiple mechanisms including alteration
of apoptosis regulating genes, alterations in the transport
and cellular turnover of the drug as well as altered ex-
pression or sensitivity of enzyme targets. COX-2 appears
to be of significance in pancreatic carcinogenesis. Several
pancreatic cancer cell lines strongly express COX-2 and
immunohistochemical studies show that 47-66% of
human pancreatic tumours overexpress COX-2 relative
to normal pancreatic tissue [23-26]. Besides COX-2 an-
other antiaopototic protein p8 is strongly expressed in
gemcitabine resistant cell lines and previous studies have
shown higher expression of p8 in PANC-1 cells [27].
Not only are antiapoptotic proteins involved in gemcita-
bine resistance but proapoptotic proteins like BNIP3 are
also involved in this chemoresistance. BNIP3, a member
of the BH3-only subfamily of Bcl-2 family proteins,
Rathos et al. Journal of Translational Medicine 2012, 10:161 Page 10 of 11
http://www.translational-medicine.com/content/10/1/161heterodimerizes and antagonizes the activity of prosurvi-
val proteins such as Bcl-2 and Bcl-xl, thus promoting
apoptosis. BNIP3 as a gene is strongly associated with
intrinsic resistance to gemcitabine and frequently down
regulated in pancreatic cancer. Also suppression of
BNIP3 by siRNA reduced gemcitabine induced cytotox-
icity in pancreatic cancer cells in vitro [28,29]. Gene and
protein expression studies done by us, demonstrated that
gemcitabine alone could induce p8 mRNA levels and both
mRNA and protein levels for COX-2, resulting in reduced
apoptosis supporting the notion that increased levels of
these antiapoptotic proteins inhibits apoptosis. Similarly
reduced levels of the proapoptotic protein BNIP3 also
support this. In addition, our results showed that gemcita-
bine followed by P276-00 treatment downregulates gene
and protein expression of the anti-apoptotic protein
COX-2, accompanied by down-regulation of p8 gene ex-
pression and at the same time upregulates the gene and
protein expression of the proapoptotic protein BNIP3.
Collectively, these results provide strong molecular
evidence in support of our hypothesis that gemcitabine
treatment followed by P276-00 could be useful in
enhancing the gemcitabine-induced killing in pancreatic
cancer cells by regulating the cell cycle proteins, antia-
poptotic and proapoptotic proteins involved in gemcita-
bine resistance in pancreatic cancers. The data indicated
that the synergy observed in vitro was extended to
in vivo antitumour efficacy studies at well-tolerated
doses and schedules. The results presented here have led
to the initiation of Phase I/II clinical trials of combin-
ation of P276-00 and gemcitabine in pancreatic cancer
patients.Conclusions
The present study describes the molecular mechanisms
underlying the synergistic inhibition of pancreatic cancer
cell growth in vitro by P276-00 and gemcitabine. More-
over, the significant in vivo antitumour activity by P276-
00 and gemcitabine together with the absence of toxicity,
provide a rationale basis for the development of novel
therapies using the gold standard gemcitabine in com-
bination with Cdk inhibitor in patients with advanced
pancreatic cancer.Additional file
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